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Thyroidhormone,operatingthroughitsreceptors,playscrucialrolesinthecontrolofnormalhumanphysiologyanddevelopment;
deviations from the norm can give rise to disease. Clinical endocrinologists often must confront and correct the consequences of
inappropriately high or low thyroid hormone synthesis. Although more rare, disruptions in thyroid hormone endocrinology due
to aberrations in the receptor also have severe medical consequences. This review will focus on the aﬄictions that are caused by,
or are closely associated with, mutated thyroid hormone receptors. These include Resistance to Thyroid Hormone Syndrome,
erythroleukemia, hepatocellular carcinoma, renal clear cell carcinoma, and thyroid cancer. We will describe current views on the
molecular bases of these diseases, and what distinguishes the neoplastic from the non-neoplastic. We will also touch on studies
that implicate alterations in receptor expression, and thyroid hormone levels, in certain oncogenic processes.
1.Preface
More than two thousand years ago, Aristotle discovered a
link between castration and disruption of male maturation.
Through extensive experimentation on bird and beast, he
hypothesized that the testes were vital to the development
of secondary male sex characteristics [1]. Excision of these
organs drastically altered body size and behavior, as well
as hair, feather, and horn growth [2]. These experiments
were the earliest seeds of what would eventually become
our current understanding of endocrinology. And from
these same beginnings arose the recognition that aberrant
endocrine signaling, through intentional intervention, acci-
dent, or pathogenic processes, could lead to disease.
Comprehension of endocrine signaling grew slowly over
the next two millennia until the mid-19th century, which
oversaw a dramatic expansion of research into endocrine
glands and their secretions. With these studies came the
ﬁrst hints of methods to clinically intervene when normal
endocrine homeostasis was disturbed. In 1849, Berthold
discovered how to undo the deed of Aristotle, showing that
castrated roosters regained their comb and wattle if the testes
were surgically transplanted back into the abdominal cavity;
Berthold correctly reasoned that the growth-enhancing
compound in the testes must be soluble and blood-borne
[3]. Similarly, the roles of the thyroid gland came to focus
when Murray,in 1891,determinedthat a patient’ssymptoms
(now known to be due to hypothyroidism) disappeared
after grafting half of a sheep’s thyroid beneath her skin.
Becausethepatient’ssymptoms disappeared quicklyafterthe
operation,Murraysurmisedhis patient’simprovementcould
not be attributed to regained function of the sheep’s gland
but rather must be “due to the absorption of the juice of the
healthy thyroid gland by the tissues of the patient” [4]. He
later suggested that injections of thyroid gland extract would
likely produce the same eﬀect, a prediction subsequently
conﬁrmed by Baumann and Roos [5]. Graves reciprocally
demonstrated that excessive thyroid gland activity leads to
the pathological process now denoted hyperthyroidism [6].
In 1915, Kendall reported the successful isolation of thyroid
hormone [7].
As more and more endocrine hormones were identiﬁed
between the mid-19th to mid-20th centuries, interest turned
toward understanding not only their synthesis and chemical
structures, but also their mechanisms of action within their2 Journal of Thyroid Research
target tissues. In the 1960s, Jensen et al. demonstrated that
radiolabeled estrogen injected into female rats localized, in
part, to reproductive target tissues, hinting at the existence
of a tissue-speciﬁc receptor for this hormone [8, 9]. In
1973, Jensen et al. demonstrated that the estrogen/estrogen
receptor (ER) complex shuttled from the cytoplasm to
the nucleus and enhanced RNA synthesis in uterine tissue
(Jensen et al. referred to it as an “alleviation of a deﬁciency
in RNA synthesis”) [10]. This was one of the ﬁrst indica-
tions that nuclear receptors could inﬂuence transcription,
foreshadowing both the appellation of “nuclear” to the term
“receptor” and the role of these receptors in gene regulation.
Additionalevidencefortheparticipationofnuclearreceptors
in transcription control soon accumulated, extending this
paradigm to glucocorticoids and thyroid hormones [11–
19]. The molecular cloning of the cDNA for glucocorticoid
receptor (GR) was reported in 1985, and, just a year later,
the cDNAs for the human estrogen receptor and thyroid
hormone receptors (TRs) were isolated and described [20–
25]. Today, 48 members of the nuclear receptor family have
been identiﬁed in humans, 49 in mice, 21 in ﬂies, and 270 in
worms [26–28].
This work ultimately led to the current model of
endocrine signaling wherein minute amounts of potent
compounds are carried from their site of synthesis through
the blood to mediate distal physiological changes. In the
cases of interest to us here, these compounds are small,
lipophilicmoleculesderivedfrom cholesterol (the androgens
ofAristotle’sobservations),highlymodiﬁedaminoacids(the
thyroid hormones), or a variety of other greasy compounds.
Nuclear receptors within the target tissues are the regulatory
ambassadors in this endocrine diplomacy:theyreceiveextra-
cellular information in the form of their cognate hormone,
bind to speciﬁc target genes, collaborate with coregulatory
partners, and initiate phenotypic change by altering the
regulation of a broad array of gene targets [10, 29, 30].
We now know that nuclear receptors have a pervasive reach
into nearly all aspects of animal biology and play key roles
not only in endocrine signaling but also in metabolic and
xenobiotic sensing [31–33]. In humans, frogs, ﬂies, and
likely every other form of metazoan life, nuclear receptors
are key regulators of development, growth, metabolism,
reproduction, homeostasis, and circadian rhythm. A recent
hierarchical clustering analysis based on nuclear receptor
expression, function, and physiology organized the known
mouse nuclear receptors into six distinct clades that span
steroidogenesis, reproduction, development, metabolism,
and energy homeostasis [34].
Notsurprisingly,departuresfromthisnormal pathwayof
endocrine signaling in humans have the potential to wreak
developmental or physiological disorder and can require
medicalintervention.Intheday-to-dayroutineoftheclinical
endocrinologist, these departures are most commonly the
consequence of too little or too much hormone production.
Although we will touch on these hormone deﬁciencies and
excesses, the main topic of this paper lies on the other side of
the equation: mutations in the nuclear receptors that receive
the hormone signals, rather than defects in the hormone
signals per se. This paper will introduce thyroid hormone
endocrinology and discuss how thyroid hormone receptors
function as members of the larger nuclear receptor family.
We will then discuss the role of TR signaling in human
disease, with an emphasis on endocrine and neoplastic
disorders.
2.Normal Thyroid HormoneEndocrinology
2.1. The Signal. In a healthy individual, thyroid hormone is
produced in response to a cascade of signals originating in
the hypothalamus, which synthesizes thyrotropin-releasing
hormone (TRH) (Figure 1). TRH induces expression of
thyroid-stimulating hormone (TSH) in the anterior pitu-
itary, which induces, in turn, synthesis and release of T3/T4
thyronine by the follicular cells of the thyroid gland. T3
and T4 are the most abundant forms of thyroid hormone
and are carried in the circulation chieﬂy as complexes
with transthyretin, serum albumin, and thyroxine-binding
globulin (TBG) [42, 43]. On arrival at a responsive cell, T3
and T4 are transported across the cell membrane primarily
by monocarboxylate anion transporters 8 and 10 (MCT8
and MCT10) [44, 45]( Figure 1). T4 can be converted to
T3 by deiodinase type 2 (DIO2) found in a variety of other
responsive tissues [46]. Although both T3 and T4 can bind
to, and modulate the activity of, intracellular TRs, T3 is
considerably more active than T4, leading many to view the
latter as a prohormone [46]. Deiodination of T3 or T4 on
their inner ring by deiodinase type 3 (DIO3) leads to their
inactivation. Interestingly, DIO1, a third deiodinase found
primarily in the liver and kidney, can remove iodines from
either the outer or inner ring and therefore can alternatively
generate or inactivate T3 [46]. It should be noted that several
metabolic derivatives ofthyroid hormone can signal through
membrane-associated G-protein coupled receptors such as
TAAR1 [47]; however, the TRs appear to represent the key
receptors for T3 and T4 and are the focus of the remainder of
this paper.
2.2. The Receptor. Once in a target cell, T3 and T4 bind
to the TR subfamily of nuclear receptors. In common with
virtually all members of the nuclear receptor family, TRs
are composed of a shared architecture consisting of an
N-terminal (A/B) domain that contains binding sites for
transcriptional coregulators, a central DNA binding domain
C responsible for target gene recognition, an intervening
“hinge” domain (D), and a C-terminal, hormone-binding
domain (E/F) (Figure 2).
2.2.1. The “A/B” Domain. The “A/B” domains of the
TRs recruit an assortment of coregulatory proteins that
can participate in ligand-independent transcription regula-
tion and/or modify the hormone-dependent transcriptional
properties of the E/F domain (see below) [48–51]. This
region is also a target of a variety of phosphorylation
events that modulate TR function [52]. Interestingly, the
(A/B) domain of many nuclear receptors appears to posses
little inherent secondary or tertiary structure but is thoughtJournal of Thyroid Research 3
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Figure 1: Regulation of thyroid hormone synthesis and activity. TRH is produced in the hypothalamus (shown in pink) and stimulates the
anterior pituitary (shown in green) to create TSH, which stimulates the follicular cells of the thyroid gland (purple) to produce T3 and T4.
T3 and T4 circulate through the blood to the peripheral tissues (see box at right), where they are transported across the cell membrane into
the cytoplasm by MCT8/MCT10 (green oval). T4 can be converted to T3 by deiodinase type 1 and deiodinase type 2 (DIO1/2, gray sphere).
Both T3 and T4 can enter the nucleus and regulate TR activity. TR is shown here as a yellow sphere bound to DNA. On most sites, TRs can
dimerize, either as homodimers or as heterodimers, with another nuclear receptor partner (NR, dark gray sphere).
instead to assume more ordered conformations on inter-
action with other proteins; it has been suggested that this
inducedﬁtphenomenonallowsthe(A/B)domaintoadaptto
diﬀerent coregulators and to diﬀerent cellular environments
[53–57].
2.2.2.The “C”Domain. The “C”domain in TRs,in common
withvirtuallyallothernuclearreceptors,iscomprisedoftwo,
highly conserved α-helical domains that are oriented and
stabilized through interactions with coordinated zinc atoms
[58–61]. The ﬁrst α-helix tucks into the major groove of
DNA and interacts intimately with a cognate hexanucleotide
sequence on the DNA [62–64]( Figure 2). The most crucial
base-speciﬁc contacts are made by the “P-box” amino acids
within this ﬁrst α-helix, and nuclear receptors with diﬀer-
ent P-box amino acids recognize diﬀerent hexanucleotide
sequences [65–67]. TRs possess an EGKG P-box and bind
most tightly to consensus AGGTCA DNA sequences in vitro
but can recognize a variety of variations on this theme; the
presence of nonconsensus sequences in nature are likely to
contributetothe speciﬁcityof target generecognition byTRs
in vivo [68].
The second α-helix in the “C” domain lies orthogonal to
the ﬁrst α-helix and stabilizes the receptor-DNA interaction
through both direct and water-mediated contacts with the
DNA phosphodiester backbone [60]. Amino acids within
or ﬂanking the second a-helix (the D-box) also can serve
as a receptor dimerization interface [60, 69]. In fact TRs
can bind to DNA as receptor monomers, homodimers, or
heterodimers with retinoid X receptors (RXRs) or other
members of the nuclear receptor family [70–74]. The best
characterized TR DNA binding sites (“thyroid hormone
response elements” or TREs) consist of two hexanucleotide
sequences(half-sites) and bind a TR-TR orTR-RXRreceptor
dimer. The sequence, orientation, and spacing of the half-
sites all contribute to proper TR recognition. In TRs, the
second α-helix is followed by a short, ﬂexible loop of amino
acids and a third α-helix; this “C-terminal extension” helix
bothmakesadditionaldimerizationcontactsandcancontact
the minor groove of the DNA, permitting recognition of
an extended DNA sequence that includes bases 5  to the
historically deﬁned hexanucleotide half-site [61, 75]. In
addition to its role in DNA binding, the “C” domain also
represents a docking surface for several known coregulatory
proteins [76].
2.2.3. The “D” Domain. The “D”domain is thought to act as
a ﬂexible linker joining together the more conformationally
and evolutionarily constrained “C” and “E/F” domains. TRs
can recognize a surprising variety of half-site orientations,
and the receptor “D” domain has been proposed to provide
therotational ﬂexibility toaccommodatethe necessary twists
and turns [70–74]. Consistent with this concept, diﬀerent
crystal structures ofTR revealdiﬀerentstructural optionsfor4 Journal of Thyroid Research
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Figure 2: Domain comparison of diﬀerent TR isoforms and
schematic of DNA- and ligand-binding domain crystal structures.
Each TR isoform is represented as a horizontal bar, from N to
C termini. Total amino acid length is indicated at right [35, 36].
Withinagivenisoform,thelocationofeachdomainislettered (A/B,
C, D, and E/F). Identical domains of TRβ1a n dT R β2a r es h o w n
in matching colors. Note the unique A/B domain of TRβ2. Below
left depicts the structure of the TR DNA-binding domain. α-helical
domains are represented as purple cylinders and coordinating zinc
atoms(Zn)assilverspheres. Below right depicts two conformations
(−T3 and +T3) of the TR ligand-binding domain, which is
composedof 12α helices; the 12th helix (dark blue cylinder, labeled
“H12”) contains the ligand-dependent activation domain. In the
−T3 conformation, helix 12 is in an extended position and the
corepressor binding groove is ﬁlled with the CoRNR-box helical
motifs found in SMRT and NCoR (red cylinder, labeled “CoR”).
In the +T3 conformation, helix 12 has rotated to close around T3
hormoneligand (shown in yellow), and a novel docking surface for
theLXXLLmotifsofatranscriptionalcoactivatorhasformed(green
cylinder, labeled “CoA”).
the “D” domain, either a ﬂexible loop or a short α-helix, as
it exists from the “C” domain [77]. The “D” domain also
possesses key nuclear localization motifs and can participate
in recruitment of several regulatory proteins, either alone or
in conjunction with the othernuclear receptordomains[77–
80].
2.2.4. The “E/F” Domain. The “E/F” domain of TRs binds
the thyroid hormone. It also forms a second receptor
dimerization surface and is a major site of coregulator
interaction (Figure 2). Although less than 35% sequence
identity is conserved among the “E/F” domains of diﬀerent
nuclear receptors, structural analysis reveals a highly shared
canonical architecture composed of a triple laminate of α-
helices surrounding a variable-sized hollow pocket lined
with hydrophobic residues (Figure 2)[ 81–88]. This pocket
varies in size and shape for diﬀerent nuclear receptors,
therebydeﬁningtheirligandspeciﬁcity. AC-terminalα-helix
(denoted helix 12 or H12) exists from this triple helical stack
and formsa short, pivotingstructure that canadoptdiﬀerent
conformations depending on presence and character of the
hormoneligand. Bindingtohormoneinducesa“mouse-trap
mechanism” whereby portionsofthe“E/F”domainconstrict
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Figure 3: Transcriptional activity of wild-type and dominant-
negative TRs. (a) In the absence of T3, wild-type TR (orange
sphere plus a grey homo- or heterodimer partner) binds to thyroid
hormone response elements (TREs-, shown as pink rectangle on
DNA), recruits a cohort of corepressor proteins (shown as a red
rectangle), and represses transcription of a given target gene (blue
rectangle). (b) In the presence of T3 (dark blue sphere), wild-type
TRs undergo a conformational change and exchange corepressor
proteins for coactivators (green oval) to activate transcription of
a target gene. (c) Dominant-negative TR mutants (shown here as
a disﬁgured lavender sphere) have defects in hormone binding,
corepressor release, or coactivator recruitment and consequently
repress transcription even in the presence of hormone and other
wild-type TRs.
around the hormone, and H12 swings shut to close oﬀ the
pocket [81, 89].
These hormone-driven conformational changes are the
principal means by which ligand regulates TR-mediated
transcriptional regulation (Figure 3). For example, the TR
“E/F” domain possess a hydrophobic surface groove com-
posed of portions of helices H3, H4, and H5 [90]. In the
absence of hormone, this surface groove can interact withJournal of Thyroid Research 5
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Figure 4: Oncogenic- and RTH-associated mutations in diﬀerent TR isoforms.(a) A schematic of wild-type TRα1 is shown as a horizontal
bar as in Figure 1; beneath, horizontal lines depict v-Erb A and several representative HCC/RCCC TRα1 mutants. As a result of fusion of
retroviral gag-sequences, the N-terminus of v-erb A is 12 amino acids shorter than TRα1. V-erb A’s 13 mutations are indicated by black
arrowheads. From left to right, they are R24H, Y44C, G73S, K90T, K186R, P191L,P203L, K233N, T342S, P363S, T370A, C378Y, and F395S.
A 9 amino-acid C-terminal deletion is indicated by vertical lines. All mutations and deletions are in relation to the avian TRα1s e q u e n c e
[24]. Under the schematic for v-Erb A, red and blue arrowheads indicate mutations found in representative HCC and RCCC mutants,
respectively, [37–39]. The nomenclature for each mutant is provided at the far right of the ﬁgure. For HCC, these mutants are hcI-TRα1
(K74E, A264V) and hcM-TRα1 (K74R, M150T, and E159K). For RCCC, these mutants are rc2-TRα1 (I116N and M388I) and rc6-TRα1
(I116N, A225T, and M388I). (b) A schematic of wild-type TRβ1 is shown as a horizontal bar as in Figure 1; beneath, horizontal lines
depict several representative HCC/RCCC TRβ mutants, RTH hot spots, and the RTH mutant, TRβ1-PV. As above, red and blue arrowheads
indicate representative mutations found in HCC and RCCC [37–39]. For HCC, these mutants are hcE-TRβ1 (M32I, C107R, and T368N),
hcI-TRβ1 (S43L, C446R), hcJ-TRβ1 (M313I), and hcN-TRβ1 (K113N and T329P). For RCCC, these mutants are rc8-TRβ1 (F451S), rc15-
TRβ1 (K155E, K411E), and rc25-TRβ1 (Y321H). Below the schematic for HCC/RCCC mutants, the locations of RTH hot spots are shown
(amino acids 234–282, 310–353, and 429–460 [36]). Representative mutants for PRTH are: R338L, R383H, and R429Q. For GRTH, these
mutations are G345S and P453S. The TRβ1-PV mutant has undergone a C-insertion at codon 448 that results in a frameshift at the C-
terminus of the receptor [40]. The location of the 16 new PV-speciﬁc amino acids is indicated by a black box on the TRβ1-PV schematic,
and the identities of these amino acids (and their wild-type TRβ1 counterparts) are shownbelow. The TRβ1-Mkar mutanthas a T insertion
at codon 436 that results in a frameshift at the C-terminus of the receptor. The locations of these new 28 amino acids are indicated by a
black box on the TRβ1-Mkar schematic, and their identities are shownbelow. Note that Mkarshares with PV the amino acid sequence from
codons 448 to 463 [41].
CoRNR-box helical motifs found in the SMRT and NCoR
family ofcorepressors, resulting inrecruitment ofthese core-
pressors. The corepressors, in turn, recruit deacetylases and
additional histone modiﬁers that, by altering the chromatin
template, lead to repression of transcription [91–94]. The
reorientation of H12 that occurs in response to binding of
hormone agonist occludes this corepressor docking surface,
releasing corepressor and simultaneously forming a novel
docking surface for the LXXLL motifs that are found in
many transcriptional coactivators, such as SRC1 [90, 95–99]
(Figure 2). These coactivators typically possesess associated
histone acetyl and methyl transferase activities that, by
appropriately modifying the chromatin, enhance transcrip-
tion. Other coactivators include the Mediator complex
(which helps recruit the general transcriptional machinery)
and ATP-dependent chromatin remodelers (which regulate
nucleosomal packaging). Diﬀerences in the shape and size
of the hormone ligand can operate the H12 conformational
toggle switch in diﬀerent fashions; hormone antagonists, for
example, induce H12 conformations that further stabilize6 Journal of Thyroid Research
corepressor binding and/or destabilize coactivator binding
[100–102].
AlthoughthisH12-drivenmechanism bywhichTRsbind
corepressors in the absence of hormone and release core-
pressors and bind coactivators on binding to T3 is the best
worked out paradigm (Figure 3), a substantial number of
genes are regulated by TRs in the inverse fashion (activated in
the absence and repressed in the presence of T3) [103–105].
Additional genes appear to be constitutively regulated up or
down by TRs in a hormone-independent manner [37]. The
precise basis for this diversity in the transcriptional response
is incompletely understood, butit presumably reﬂects mech-
anisms by which the nature of the DNA binding site, and/or
the presence of additional transcription factors on the target
gene,canaltercoregulatorrecruitment orfunction. Itshould
be noted that thyroid hormone receptors not only operate
as transcription factors but also mediate nonnuclear eﬀects
by interacting with other proteins; although not the focus of
this review, this aspect of TR function will arise again in our
discussion of the TRβ-PV mutant (Figure 4)[ 106].
3.DiversiﬁcationofSignal Reception:
The TRIsoforms
TRs in humans are encoded by two distinct genetic loci: TRα
on chromosome 17 and TRβ on chromosome 3. Alternative
splicing and promoter usage produces additional diversity,
leading to the synthesis of a series of TR “isoforms,”
the most studied of which are TRα1, TRβ1, and TRβ2
[35, 106]( Figure 2). All three bind T3 and can modulate
expression of target genes in response to this hormone (not
all splice variants do so; the TRα2 splice form, e.g., does not
bind T3 and appears to mediate a hormone-independent
mode of transcriptional regulation [35, 106]). Though
virtually all cells express some form of TR, the ratios of the
diﬀerent isoforms vary in diﬀerent tissue types and during
development [106, 107]. TRα1 is expressed in the early
stages of embryonic development, and is widely distributed,
althoughparticularly abundantin skeletalmuscleand brown
fat. TRβ1, in contrast, appears later in development and is
present at the highest levels in the liver and kidney. TRβ2i s
restricted to the pituitary, hypothalamus, sensory cells in the
inner ear, and in the cone cells of the retina [35, 106–110].
TR knockout mice have helped delineate each isoform’s
role in thyroid hormone action. Mice missing the TRα1
isoform, for example, have cardiac abnormalities and lower
body temperatures, whereas TRβ−/− animals have hearing
defects and a loss of negative feedback regulation of the
hypothalamus/pituitary/thyroid axis (e.g., high T3/T4 and
unsuppressedTSHandTRHlevels)[111–114].Ofnote,mice
bearing genetic disruption of all TR isoforms also present
with high circulating T3/T4 and unsuppressed TSH levels
(apparently due to the loss ofTRβ2 in the hypothalamus and
pituitary)butotherwise displayfewersystemic abnormalities
than do the TRβ-speciﬁc isoform knockouts. Presumably
the loss of the peripheral TRα1a n dT R β1r e s p o n s ei n
these combined knockout mice renders them resistant to
the otherwise detrimental eﬀects of their elevated T3/T4
levels [115, 116]. In fact, chemically or genetically induced
hypothyroidism also presents as a much more severe syn-
dromethan doestheTRα/TRβ combinedreceptorknockout,
indicating that the presence of unliganded TRs is more
disruptive physiologically than is the complete lack of TR
function. Taken as a whole, these genetic studies indicate
that the diﬀerent isoforms mediate both shared, and speciﬁc
physiologicaland developmentalfunctionsand thatTRsplay
major biological roles even in the absence of T3.
Although there appears to be signiﬁcant overlap between
the target genes regulated by the diﬀerent TR isoforms, the
detailed transcriptional response on a given gene can diﬀer
for each isoform [37, 117, 118]. For example, TRα1c a n
induce expression of certain genes more strongly than does
TRβ1, whereas these isoforms confer nearly equal activity on
other genes [37]. Similarly, TRβ2 fails to repress and instead
activates certain genes under T3 conditions that confer
repression by TRβ1o rT R α1[ 50, 119–122]. These gene- and
isoform-speciﬁc transcriptional responses are likely to reﬂect
diﬀerences in the coregulatory factors that are recruited by
each isoform once bound to a given target gene.
4.A FailedResponse:TRMutationsand
Resistanceto Thyroid Hormone(RTH)
Syndrome
Circulating T3/T4 levels are tightly controlled by a negative
feedback loop wherein surges of thyroid hormone bind
to TRs in the hypothalamus and pituitary, which then
suppress TRH and TSH production and, as a consequence,
repress further release of T3/T4 (Figure 1). Production of
too much or too little thyroid hormone causes a number of
clinically important endocrine disorders. In Graves’ disease,
for example, a hyperstimulated thyroid overproduces T3
leading to cardiac abnormalities, palpitations, fatigue,
weight loss, dyspnea, myxedema, and muscle wasting
[123, 124]. Conversely, insuﬃcient T3 (hypothyroidism)
produces depression, weight gain, edema, thickened speech,
reduced cognition, cold intolerance, and, in a neonate,
cretinism (a disorder marked by retarded physical and
mental development) [124–126].
The consequences of over- or underproduction of cir-
culating T3/T4 had been recognized for over a century
when Refetoﬀ et al., in 1967, reported an intriguing para-
dox in a study of two siblings with goiter, short stature,
deafness, mutism, and bone deformations [127]. Although
these symptoms shared several characteristics with hypothy-
roidism, both patients had high concentrations of thyroid
hormone in the blood. Refetoﬀ et al. suggested that the
patients’ tissues might be deﬁcient in their ability to sense
T 3a n dc o i n e dt h ep h r a s e“ R e s i s t a n c et oT h y r o i dH o r m o n e
(RTH)Syndrome: [127, 128]. This was soon conﬁrmed, and,
since then, RTH syndrome has been recognized as an auto-
somal dominant genetic disease that aﬀects approximately 1
in 40,000 people worldwide [36, 129].
ThevastmajorityofRTHcaseshavebeentracedtomuta-
tions in the TRβ isoform (Figure 4)[ 130–134]. As of2010, at
least 137 diﬀerent RTH-TRβ mutations have been identiﬁed,Journal of Thyroid Research 7
distributed among more than 300 families [36, 128, 135–
138]. Despite this genetic diversity, virtually all of these
RTH-TRβ mutations appear to share one key property: they
encodemutantreceptorsthatfunction asdominant-negative
inhibitors of wild-type TR function [36]( Figure 3). RTH
syndrome is, in fact, largely a disease of heterozygotes, and
it is believed that RTH-TR mutant receptors interfere with
normal T3 signaling by competing with the wild-type TRs
expressed in the same cells from the unaﬀected TR alleles.
Only two cases of patients homozygous/hemizygous for the
TRβ mutation have been published: one was the product of
a cousin marriage, and the other was born to a mother with
goiter and a father of indeterminable genotype [139, 140].
RTH-TRβ mutants can interfere with both wt TRα1
and wt TRβ1 functions and are likely to mediate both
isoform-speciﬁc and nonspeciﬁc eﬀects in vivo, depending
on the tissue and on the target gene. Interestingly, no RTH
mutations have been mapped to TRα in humans, and,
when TRβ RTH mutations are artiﬁcially targeted to TRα1
in mice, they do not produce RTH but generate instead
a distinct slew of neoplastic and metabolic defects [141–
145].Althoughlessfrequentlycataloged,andpresentingwith
distinct symptoms, genetic defects in the MCT8 transporter,
orin the incorporation ofselenocysteines into the active sites
of deiodinases, can also lead to defects in thyroid hormone
signaling [36, 44]. This paper, however, will focus on RTH
syndromes that arise due to lesions in the TRβ gene.
ThegeneticlesionsresponsibleforRTHsyndromecluster
in several “hot spots” mapping within the “D” and “E/F”
domains of TRβ and result in defects in the hormone-
driven release of corepressors and acquisition of coactivators
(Figure 4)[ 79, 146–149]. In many cases, these mutations
map to the hormone binding pocket and impair or eliminate
the ability of the RTH-TRβ mutant to bind T3/T4 [36].
Although somewhat more rare, additional RTH mutants
have been identiﬁed that retain a near wild-type aﬃnity for
T3/T4 but are defective in the conformational machinery
that couples hormone binding to corepressor release and/or
coactivator recruitment [150]. For example, proline 453 in
TRβ1i sa ni m p o r t a n tp i v o to nw h i c hH 1 2r e o r i e n t si n
response to hormone agonist (Figure 4). Diﬀerent amino
acid substitutions at P453 have been identiﬁed in multiple
human RTH syndrome kindreds; RTH-TR mutants bear-
ing these substitutions retain signiﬁcant T3 binding, but
nonetheless exhibit defects in corepressor release, presum-
ably due to a failure of H12 to properly reorient in response
to bound hormone [151–155].
It is important to note that the symptoms of RTH
syndrome are not identical to those of either a homozygous
or heterozygous null mutation of TRβ. Instead it is the
ability of the RTH syndrome TRβ mutants to function as
dominant-negatives that plays a critical role in producing
the disease phenotype. Is it the failure of the mutant TRβ
to release corepressor, or to bind coactivator, that leads to
this dominant-negative phenotype? In most RTH mutants
tested, experimental inhibition of corepressor binding by
biochemical or genetic manipulation reduces dominant-
negative activity [150, 156]. Consistent with these ﬁndings,
RTH patients with TR mutants that interact weakly with
corepressors generally have more minimal disease symptoms
than those with a strong corepressor interaction [157].
Nonetheless, a defect in coactivator binding (rather than in
corepressor release) represents the primary defect in at least
one RTH-TR mutant [147] and appears to contribute to
the dominant-negative phenotype exerted by several other
RTH-TR mutants (see Pituitary Resistance, below). It is
also important to note that there are multiple forms of
corepressor, and RTH mutants can display alterations in
corepressor selectivity, rather than global defects in core-
pressor release. For example, NCoR and SMRT are closely
related corepressor paralogs found in many cells. Wild-type
TRs preferentially interact with NCoR, whereas the Mkar
RTH mutant of TRβ (representing a C-terminal frame shift
mutation), signiﬁcantly reduces NCoR binding, but results
in an increase in the SMRT interaction (Figure 4)[ 41].
NCoR and SMRT also undergo alternative mRNA splicing,
and several RTH-TRβ mutants diﬀer from wtTRβsi nt h e i r
ability to bind to these diﬀerent corepressor splice variants
[38, 158, 159]. This point will be addressed again in our
discussion of oncogenic versions of TR (below).
5.DifferentPathsto Resistance:Generalized
versusPituitaryRTHDisease
RTH has been divided clinically into two main subtypes,
generalized (GRTH) versus pituitary (PRTH) [118, 130,
160–164]. GRTH is characterized by a broad insensitivity
to thyroid hormone; as a result GRTH patients display
some characteristics suggestive of hypothyroidism (e.g.,
short stature, goiter, and hearing impairments, reﬂecting
an impaired T3 hormone response in peripheral tissues)
but also have inappropriately high circulating levels of T3
and T4 and nonsuppressed TSH (a consequence of a loss
of negative feedback in the hypothalamus/pituitary/thyroid
gland axis) [35]. In essence, GRTH patients make more T3
and T4 than normal, but “do not know it,” and present
in some fashion as if they make too little. In contrast, in
PRTH patients, negative feedback sensing in the hypothala-
mus/pituitary/thyroidgland isselectively impaired (resulting
in high levels of circulated T3/T4), whereas the peripheral
tissue response remains relatively intact (resulting in symp-
toms of hyperthyroidism, such as cardiac palpitations, heat
intolerance, and nervousness) [35, 165, 166]. Thus, PRTH
patients make too much T3 and T4, and “do know it,” often
to the point of peripheral thyrotoxicity.
These subtypes are not completely discrete: a given
mutation can manifest as either GRTH or PRTH in diﬀerent
individuals, or within a given individual at diﬀerent times
[36]. Nonetheless certain RTH mutations are more often
associated with one or the other form of disease, an
observation that has been recently conﬁrmed in a mouse
knock-in model of PRTH syndrome [167]. Notably, the
mutations most often associated with GRTH typically map
to amino acid substitutions in the hormone binding or
pivot/H12 domains of TRβ and can be explained concep-
tually through their potential to interfere with hormone8 Journal of Thyroid Research
binding, corepressor release, or coactivator recruitment. In
contrast,themostextensivelycharacterized PRTHmutations
map to a set of three arginines that form charged clusters
on the surface of the TR “E” domain. In normal TRs, these
arginines have been implicated in stabilizing the overall
conformation of the “E/F” domain and also as important
contacts in receptor homodimerization [168, 169].
Several explanations have been advanced for how PRTH
mutations might impair T3 negative feedback in the
hypothalamus/pituitary/thyroid axis while sparing the T3
response in the peripheral tissues. One proposal focuses on
the observations that (a) TRβ1 forms homodimers more
eﬃciently than does TRβ2, (b) TR homodimers recruit
corepressors more eﬃciently than do TR/RXRheterodimers,
and (c) many PRTH mutations impair homodimerization
but retain the ability to form heterodimers with RXRs [94,
167, 170–177]. By this scenario, the diminished homodimer-
ization properties of the PRTH mutants would favor TR-
mediated activation over TR-mediated repression, resulting
in a loss of repression of T3 synthesis in the hypothalamus
and pituitary (producing increases in circulating T3 levels),
yet enhancing T3-mediated positive gene regulation, result-
ing in the symptoms of peripheral thyrotoxicity characteris-
tic of PRTH.
Alternatively, it is known that the hypothalamus and
pituitary express primarily the TRβ2 splice form, whereas
most peripheral tissues, such as liver, muscles, and kidneys,
express primarily TRβ1[ 35, 106, 178–183]. TRβ2d i s p l a y s
an enhanced ability to respond to T3 than does TRβ1,
a phenomenon that may permit the hypothalamus and
pituitary to sense, and suppress, surges of T3 before these
elevatedhormone levelssaturate the more widely distributed
TRβ1i s o f o r m s[ 122, 184]. TRβ1a n dT R β2s h a r et h es a m e
“C,” “D,” and “E/F” domains, and so RTH mutations are
expressed as both splice forms. We have suggested that
PRTH mutations have a more severe impact on the T3
response of TRβ2 compared to their impact on TRβ1,
r e s u l t i n gi na ni n c r e a s ei nt h y r o i dh o r m o n el e v e l s( d u et o
the impaired TRβ2-mediated negative feedback response in
the hypothalamus/pituitary) while nonetheless conferring
at h y r o t o x i ce ﬀect in peripheral tissues (mediated by the
less-impaired TRβ1s p l i c ef o r m )[ 122]. As is most often
the case with competing scientiﬁc theories, it is likely that
both models play a role in the actual genesis of PRTH
disease.
6.AStillDarker Sideto AberrantT3 Sensing:
TRsand TheirMutationsin Oncogenesis
In an ironic twist of history, TRs were linked to cancer
before they were everrecognized as endocrine receptors. The
avian erythroblastosis retrovirus (AEV) was ﬁrst identiﬁed
in 1935 as a retrovirus that could induce erythroleukemias
and ﬁbrosarcomas in infected chickens [185]. By the early
1980s it was realized that the oncogenic proclivities of
AEV mapped to two viral oncogenes, v-Erb A and v-
Erb B, that worked together to induce oncogenic trans-
formation [186–188]. In 1986, v-Erb A was shown to be
a retrovirally acquired, mutated version of avian TRα1
(Figure 4)[ 24, 25], establishing the precedent that mutated
versions of TR can participate in the initiation or progres-
sion of oncogenesis. Mutated versions of TRs have been
subsequently linked to hepatocellular carcinoma (HCC),
renal clear cell carcinoma (RCCC), pituitary adenomas,
and thyroid malignancies (Figure 4)[ 189–192]. Conversely,
wt TRs can function as tumor suppressors, and loss of
wt TR expression has been associated with these and
other tumors [193]. We will discuss these malignancies in
turn.
6.1. V-Erb A. Acutely transforming retroviruses cause neo-
plasia by acquiring, mutating, and inappropriately express-
ing host cell genes involved in the control of normal cell
proliferation or diﬀerentiation. AEV represents a model by
which two virally acquired cell genes, v-Erb A and v-Erb
B, cooperate to induce neoplasia [187, 194–196]. V-Erb B
is a mutated version of the avian epidermal growth factor
(EGF) receptor, a cell surface tyrosine kinase that induces a
cascade of mitogenic signals in response to extracellular EGF
[188,197].ThroughlossofitsextracellularregulatoryandC-
terminal domain, compounded by internal point mutations,
v-Erb B has acquired a constitutive kinase activity that can
induce proliferation of immature erythroid cells and ﬁbrob-
lasts even in the absence of EGF. V-Erb A is, as noted above,
a mutated version of chicken TRα1. However, in contrast to
the constitutive activation seen for v-Erb B, the mutations in
v-Erb A have turned the latter into a constitutive repressor
[198–201]. V-Erb A cooperates with v-Erb B in oncogenesis
bysuppressingdiﬀerentiationofAEV-infectederythroidcells
and by promoting the growth and life span of AEV-infected
ﬁbroblasts.
The basis of the dominant-negative activity of v-Erb
A is obvious on inspection: the H12 helix toggle switch
critical for corepressor release and coactivator recruitment
by the wt TRα1 is deleted from the v-Erb A coding
region (Figure 4)[ 24, 25]. In addition to this C-terminal
deletion, v-Erb A has sustained a fusion at its N-terminus
with sequences derived from the retroviral “gag” pro-
tein and 13 internal amino acid substitutions (Figure 4)
[24, 25]. Several of these substitutions map to the hor-
mone binding pocket, virtually abolishing the ability to
bind T3 and further favoring corepressor over coactiva-
tor binding, whereas others map to the “A/B” and “C”
domains.
Thus,inmany ways,onewouldexpectv-ErbAtooperate
as a particularly virulent version of an RTH mutant. Why
then does v-Erb A function in neoplasia, whereas the RTH
mutants induce primarily endocrine disorders? Neither the
avian origin nor the TRα1 isoform backbone of v-Erb A
fully explains this phenomenon. Instead, the acquisition
of oncogenesis by v-Erb A appears to result in large part
from changes in its DNA recognition domains. V-Erb A
has sustained two amino acid substitutions within the P-
and D-boxes of the “C” domain that play crucial roles in
DNA binding speciﬁcity, as well as two additional amino
acid substitutions in the “A/B” domain that can modifyJournal of Thyroid Research 9
DNA recognition by the adjacent “C” domain [202]. As
a consequence, v-Erb A possesses an altered speciﬁcity for
artiﬁcial DNA response elements in vitro compared to wt
TRα1 and an altered target gene speciﬁcity in transfected
cells [196, 203–207]. It is likely that the oncogenic properties
of v-Erb A reﬂect these changes in DNA recognition,
permitting the viral protein to target a distinct set of
“neoplastic” genes that diﬀer from the “endocrine” genes
normally targeted by TRα1. These novel v-Erb A targets
may include those regulated by other nuclear receptors
(such as retinoic acid receptor), or by other, nonreceptor
transcription factors [194]. Consistent with this proposal,
replacement of portions of the “C” domain of v-Erb A
with the corresponding wt TRα1 sequences severely inhibits
oncogenic transformation by AEV [208]. It should be noted
that these DNA binding domain mutations probably work
together with the other mutations in v-Erb A that favor
repressionbydeletingH12,inhibitingT3binding,enhancing
homodimer formation, and widening the ability of v-Erb
A to bind to both SMRT and NCoR forms of corepressor
[205].
6.2. Hepatocellular Carcinoma. The neoplastic properties
of v-Erb A were viewed as an obscure tidbit of avian
retrovirology exotica until eerily analogous TR mutants
were discovered in a variety of human tumors. The ﬁrst
among these was human hepatocellular carcinoma (HCC).
Worldwide, HCC ranks 5th out of all neoplasias for
number of cases and third for number of deaths [209].
HCC can manifest as a medley of symptoms, including
upper abdominal pain, weakness, weight loss, and jaundice
[210]. Infection with hepatitis B or C virus is one of
the major risk factors for HCC, along with cirrhosis, and
exposure to aﬂatoxin, a highly mutagenic fungal compound
often found in stores of contaminated grains or nuts
[211].
Though the risk factors for HCCare known, the molecu-
lar mechanisms responsible for subsequent tumor initiation
and progression are not fully understood. Alterations in
a variety of tumor suppressors and oncogenes have been
identiﬁed in HCC, as have a variety of chromosomal losses,
gains, and translocations [212–216]. Most provocatively for
the topic of this paper, however, is that TR mutants have
been identiﬁed at high incidence in both HCC cell lines
and in solid tumors [189, 217]. One study found that 65%
of examined tumors had mutations in TRα and 76% had
mutations in TRβ, with a signiﬁcant subgroup of these
tumors bearing mutations in both loci [189].
The HCC-TRmutants,when analyzed, resembleinmany
of their properties the RTH paradigm: they are impaired
for transcriptional activation, many display defects in T3-
driven corepressor release and/or coactivator binding, and
the majority can function as dominant negative inhibitors of
wild-type receptor activity in reporter gene assays (Figure 4)
[39]. Unlike RTH syndrome, however, the TR mutations in
HCC are not inherited, but instead arise de novo during the
progression of the HCC tumors [189]. Also in stark contrast
to RTH syndrome, the vast majority of HCC-TR mutants
analyzed had sustained two or more genetic lesions, with at
leastonelesionlocatedsoastoimpactDNArecognition(i.e.,
in the “A/B” or “C” domains). Indeed, two of the HCC-TR
mutants studied were able to bind in vitro to DNAsequences
not recognized by the wild-type receptors [39].
This suite of molecular defects suggested a potential
role for these HCC-TR mutants in the mismanagement of
transcription of genes not normally under T3 regulation.
Gene expression analysis of hepatoma cell lines expressing
speciﬁc HCC-TR mutants conﬁrmed this supposition by
demonstrating that these mutants regulate a distinct set
of genes from that regulated by the corresponding wild-
type receptors [37]. Analysis of the HCC-TR target gene
set revealed several provocative features. A subset of genes
normally regulated by wt TRs were not targeted by the
HCC-TR mutants tested; conversely, the HCC-TR mutants
regulated a panel of novel genes that were not targets of
wt TR regulation. Several genes were targeted by each of
the HCC-TR mutants, such as AGR2, DKK1, CDC7AL, and
SLC2A2and were repressed inboththeabsenceand presence
of hormone compared to the wild-type receptors [37].
Interestingly, HCC-TR target genes included not only genes
that were constitutivelyrepressed by the mutantreceptors, as
expected from prior reporter gene assays, but also genes that
were constitutively activated, including GNG12, GPC3, and
KCNAB2 [37]. At least several of these aberrantly regulated
genes have been previously implicated in cancer [37].
Therefore, although the TR mutations associated with HCC
appear toimpede the abilityofthe receptorto respond to T3,
they do not necessarily prevent the receptor from mediating
hormone-independent transcriptional eﬀects, both down
and up.
Although the role of many of the HCC target genes in
oncogenesis remains to be determined, it was notable that
the HCC-TR mutants gained the ability to activate several
genes known to play proproliferative roles (CSF1, NRCAM,
andCX3CR1)andtorepressseveralgenesknowntofunction
as tumor suppressors (DKK1, TIMP3). Conversely, several
potential proproliferativegenes repressed by wt TRs were not
repressed by the HCC-TR mutant (e.g., GPC3, expression
of which has been linked to cell proliferation in liver), and
several potential tumor suppressor genes activated by wt TR
were not activated by the HCC-TR mutant (e.g., TIMP3)
[37].
These ﬁndings further extended the conceptual model
ﬁrst put forward for v-Erb A: TR mutants associated with
disease act, at least in part, as dominant-negative inhibitors
of normal TR action. In the absence of any additional
changes, these TR mutants can cause endocrine disorders
such as RTH syndrome. Acquisition of yet-additional lesions
that impact the DNA recognition domains of the receptor,
as observed for v-Erb A and for the HCC-TR mutants
described above, appears to unleash a previously cryptic
oncogenic function in the TRs, permitting the mutant
receptors to extend their regulatory reach to genes capable
of contributing to leukemogenesis and hepatocellular
carcinogenesis. Drawing this conceptual link between
v-Erb A and the HCC-TR mutants tantalizingly closer,
systemic expression of v-Erb A in transgenic mice under10 Journal of Thyroid Research
a β-actin promoter results in a high incidence of HCC
[218].
Given theevidencethatmultiplymutatedTRscontribute
to multiple neoplastic diseases, are there other forms of
cancer in which TRs might play a role? To address this
question, we next turn our discussion to renal clear cell
carcinomas.
7.The Internist’s Tumor:RenalCell
Carcinoma(RCCC)
RCC accounts for ∼3% of all adult malignant diseases [219].
In men, it is the 7th most commonly occurring cancer; in
women, it is the 9th [220]. Once known as “the internist’s
tumor” for its ability to produce an assortment of internal
maladies and symptoms (ﬂank pain, blood in the urine,
fever, and palatable abdominal masses, to name a few), RCC
actuallyencompasses adiverseassortment oftumorsubtypes
[221]. The most common of these subtypes (∼75–80%) is of
the clear cell variety and is abbreviated RCCC (or ccRCC)
[219]. The name is derived from the appearance of the
cytoplasm after histological prep of cancer tissue: high lipid
content results in a clearsolution [219]. Risk factors for RCC
includetobaccouse,highbodymassindex,andhypertension
[219, 222–226]. Though methods of detecting renal tumors
have improved in recent years, worldwide incidence and
mortalityrates are ontherise [220].MetastaticRCCishighly
resistant to conventional treatments (chemotherapy, radi-
ation, and hormone therapy) and survival outcomes after
diagnosis are typically less than one year [220, 227]. Though
understanding the molecular basis of this disease has greatly
advanced treatment options, therapy-refractory tumors typ-
ically develop 6–15 months after initial clinical intervention
[228].
Approximately 80% of RCCCs bear inactivating muta-
tions in the von Hippel Lindau gene (VHL)[ 229]. VHL
encodes the targeting component of an E3 ubiquitin ligase
complex,which marks thehypoxiainduciblefactor(HIF)for
degradation. Normally, HIF functions as an oxygen-sensing
transcription factor; under hypoxic conditions it activates an
array of genes involved in the formation of new blood vessels
[230–232]. When VHL is inactivated, HIF accumulates
and proangiogenic factors are transcribed unchecked; this
contributes to the highly vascular tumors characteristic
of RCCC [233]. Additionally, VHL has been implicated
in spindle misorientation and chromosome instability; a
defective VHL protein may, therefore, drive formation of
additional tumor-promoting mutations [234]. In RCCCs
with this genetic root, one defective VHL allele is typically
inherited, and the other is deleted or mutated somatically.
Although VHL inactivation is considered the predom-
inant molecular change associated with development of
RCCC, it alone is not suﬃcient to cause cancer in mice
[235, 236]. It is likely that VHL inactivation serves as the
ﬁrst step towards tumorigenesis and that additional steps, or
“hits,” are required for tumor progression [237]. In fact, an
intriguing diversity of TR mutations, deletions, and aberrant
mRNAexpressionpatternshavebeenobservedinRCCC.For
example,ananalysis of71RCCCtumorsfoundcharacteristic
deletions at 3p26 and 3p24, which are home to VHL and
TRβ, respectively [238]. Analysis of TR mRNA expression
in RCCC tumor tissues revealed a signiﬁcant reduction of
TRβmRNAinthemajorityofsamplestested(althoughpara-
doxically, TRβ mRNA was overexpressed in several samples)
[239]. Reduction of TRα mRNA was also observed in several
RCCC tumors, although complete loss of the TRα locus
on chromosome 17 was rare [238–240]. And, of greatest
relevance to the topic of this paper, mutations in both TR
isoforms have been identiﬁed in ∼40% of RCCC tumors
examined, in TRα,T R β,o rb o t h[ 190]. It is therefore likely
thatdefectsinTRfunctioncanserveasa2ndhitthattriggers,
or participates in, the transition from renal cyst to clear cell
carcinoma.
Ten diﬀerent RCCC-TR mutants have been studied in
molecular detail [190]. In common with HCC, the majority
oftheseRCCCmutantscontainmorethanonegeneticlesion
each, with at least one or more of these lesions frequently
mapping to the “A/B” or “C” domains; nonetheless, no two
identical TR mutations have been isolated to date from the
two diﬀerent forms of neoplasia. The majority of the RCCC-
TR mutants tested display hormone binding and coregulator
release/acquisition defects in vitro and can function as domi-
nant negatives in reporter geneassays (Figure 4)[38].Several
RCCC-TR mutants also display a gain in their speciﬁcity
for certain splice forms of SMRT and NCoR compared to
the wild-type receptor [38]. The multiple genetic lesions
carried by a given mutant receptor can work together
to contribute to the overall dominant-negative phenotype
[38].
Do the mutations in the “A/B” and “C” domains of the
RCCC-TR mutants alter their DNA speciﬁcity? Consistent
with this idea, nuclear extracts from RCCC tumors were
found to be impaired in their ability to bind to consensus
TREs compared to extracts from wt tissues [190]. Expression
array analyses of cells stably transfected with RCCC mutant
receptors are in progress to determine if there are changes
in target gene speciﬁcity (Rosen, Chan, and Privalsky
unpublished observations).
8.Thyroid Neoplasia
At h i r de x a m p l eo fa na s s o c i a t i o no fah u m a nn e o p l a s i a
with mutations in the TR loci was revealed by studies
of papillary thyroid malignancies. Almost 63% of these
malignancies were found to have mutations in TRα,a n da
remarkable 94% in TRβ; incontrast 22% and 11%of thyroid
adenomas bore mutations in these isoforms, respectively,
and no mutations were found in normal thyroid controls
[191, 241]. This pattern is most consistent with a role of
the TR mutants in cancer progression, rather than initiation.
Further analysis demonstrated that the majority of these
mutated TRs lost transcriptional activation function and
displayed dominant-negative activity when coexpressed with
their normal TR counterparts [191, 241]. Many, but not
all, of these mutants contained multiple genetic lesions,
with one tumor possessing 5 diﬀerent lesions within a
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and 2 in TRβ1[ 191]. In many of these mutants, lesions
included at least one mutation within the “A/B” or “C”
domains. The eﬀects of these mutations on DNA binding
in vitro, or target gene speciﬁcity in cells, have not been
reported.
9.PotentialCracksinthe Wall Separating
RTHSyndromefromHCC,RCC,and
Thyroid Malignancy
The narrative to this point may have led the unwary reader
to the conclusion that the absence or presence of DNA
binding domain mutations determines if a given dominant-
negative TR mutant induces endocrine or neoplastic disease.
However, there is some evidence that this phenomenon
may not be absolute. Although not associated with overt
neoplasia,RTH-TRmutationsinhumansoftenleadtogoiter,
a nonneoplastic hyperplasia of the thyroid gland in response
to the loss of T3/T4 feedback regulation. Further, a very
strong dominant-negative RTH-TRβ mutant, denoted PV
and representing a frameshift at the C-terminus of the
receptor, causes not only severe disruption of the pituitary-
thyroid axis and goiter, but also TSH-omas, and metastatic
follicular thyroid carcinoma in homozygous-mutant mice
[40, 242–245]. The “A/B” and “C” domains of the PV
mutant are fully wild type in sequence (Figure 4), suggesting
that strong, dominant-negative RTH-TR mutants may have
an inherent oncogenic potential that is rarely displayed in
humans (where homozygosity for the RTH mutation is
very unusual) but can uncloak when presented with an
appropriate opportunity.
Subsequent analysis of the PV/PV mutant mice revealed
several mechanisms by which the mutant receptor appears
to be mediating oncogenesis; signiﬁcantly, none of these
involved the classic mode of direct binding of the TR mutant
receptors to DNA [163]. The PV mutant was found to
heterodimerize with, and inhibit, another member of the
nuclear receptor family, peroxisome proliferator-activated
receptor-γ, removing an antiproliferative signal [246, 247].
Many nuclear receptors exert nongenomic functions outside
of the nucleus, and the PV mutant also induced one of
these: the phosphatidyl-inositol 3 kinase/AKT pathway [248,
249].ThePVmutantalsomakesprotein-proteininteractions
with β-catenin and pituitary tumor transforming gene
protein, increasing levels of these proteins by inhibiting their
degradation [249–252]. Finally, through protein-protein
interactions with the CREB transcription factor, the PV-
TRβ m u t a n tw a sa b l et oi n d u c ec y c l i nD 1[ 245]. These PV-
TR studies raise the possibility that similar TR signaling
pathways,unrelated to DNArecognitionper se, may also play
a role in HCC-TR and RCCC-TR oncogenesis.
1 0 .U p sa n dD o wn so fW i l d - T ypeT RE x p r e s s i o n
inOncogenesis
The impact of TRs on neoplasia is not restricted to scenarios
involving receptor mutants. Wild-type TRs can act as tumor
suppressors in many contexts, and losses in wild-type recep-
tor expression appear to precipitate, or otherwise contribute
to, several classes of neoplasia. For example, a double
knockout of both TRα and TRβ in mice results in a higher
incidence of follicular thyroid carcinoma and increased
aggressiveness in a skin cancer model [253, 254]. Changes
in TRα1 levels have been shown in 49% of human gastric
cancers analyzed by immunoblotting [193]. Reduction in
TRβ1 levels or changes in subcellular localization have been
reported in colorectal cancers [255]. In several cases these
changes in TR expression levels were associated with alter-
ations in the restriction pattern of the TR gene, suggesting
that loss of expression might reﬂect an underlying genetic
event.Inothercases, TR expression appears to besuppressed
epigenetically by hypermethylation of the promoter region
of the TR gene; for example, biallelic inactivation of TRβ
expression by promoter methylation has been found in
human breast cancers [192, 256]. Notably, reintroduction
of wild-type TRβ into HCC or mammary carcinoma cell
lines that have lost endogenous TR expression retards
proliferation, results in partial mesenchymal to epithelial
transitions, and suppresses invasiveness, extravasation, and
metastasis in nude mice [253, 257].
11.Thyroid HormoneStatusand Cancer
As noted above, changes in TR expression and function
are associated with a wide variety of neoplastic events. Can
changes in thyroid hormone levels exert similar eﬀects?
Answering thisquestionhasproventobecomplexandsome-
what contentious. In clinical studies, hypothyroidism has
beenreported tocorrelate witha lowerrisk ofprimary mam-
mary carcinoma and a reduction in progression to invasive
disease [258]. Pharmacologically induced hypothyroidism
has similarly been reported to yield an improved survival
in glioblastoma when used together with tamoxifen [259].
Consistent with hypothyroidism being beneﬁcial, T3 has
been reported to induce the proliferation and invasiveness of
severaltypesoftumor-derivedcellsincultureorinxenograft
models, including HCC-derived cells [253].
In contrast, however, other studies indicate that low
thyroid hormone levels increase the risk of HCC in humans,
and high T3/T4 are therapeutic [260]. Dating back to the
late 18th century, administration of thyroid extract was
often used in conjunctionwith oophorectomy as a treatment
for breast cancer [261–263]t h o u g hi t se ﬃcacy was not
well established [264]. More recently, T3, operating through
TRβ1,has beenshown toretardtheproliferation,anchorage-
independent growth, and invasiveness of mammary cancer
cells in culture [265]. Similarly, long-term hypothyroidism
in women has been associated with an elevated risk of
HCC [266], whereas T3 administration can reduce HCC
progression in animal studies [267], and T4 has shown some
success in reducing the risk of colorectal cancer [268].
Clearly “results may vary!” It is likely that the impact
of thyroid hormone diﬀers in diﬀerent types of cancer and
may control diﬀerent aspects of the same cancer (prolif-
eration, diﬀerentiation, invasion, metastasis, apoptosis, and12 Journal of Thyroid Research
senescence) diﬀerently. For example, the investigators that
have shown T3 to be promitogenic in rodent liver have
also shown that T3 suppresses formation of preneoplastic
nodules in a diethylnitrosamine rat model of HCC; T3
is therefore likely to be exerting both proproliferative and
prodiﬀerentiation eﬀects on liver [269]. It is worth noting
that T3 also induces both diﬀerentiation and proliferation in
several other contexts, such as the gut [270]. As is virtually
always true in science, more studies will be required to fully
revealalloftheintricatewebofbiologicalprocessesregulated
by T3 and its receptors.
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